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ABSTRACT
HIV drug resistance has been one of the major
obstacles to HIV eradication and has
contributed to the need for the constant
development of new antiretroviral drugs over
the past 25 years. With the recent approval of
dolutegravir for human therapy by the U.S.
Food and Drug Administration, health
practitioners may soon have access to three
integrase strand transfer inhibitors to treat
individuals living with HIV. Here, we review
the use of raltegravir, elvitegravir, and
dolutegravir for use in first- and second-line
HIV treatment regimens and the issue of HIV
resistance against integrase inhibitors.
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INTRODUCTION
Current highly active antiretroviral therapy
(HAART) against HIV infection has, until
recently, typically consisted of two reverse
transcriptase inhibitors and a ritonavir-boosted
protease inhibitor or a non-nucleoside reverse
transcriptase inhibitor (NNRTI) for treatment-
naı¨ve adults [1]. HIV drug resistance threatens
the long-term efficacy of HAART in both
developed and developing country settings
(reviewed in [2–4]) and this has led to the
development of a new class of drugs termed
integrase inhibitors. As is the case for all
Electronic supplementary material The online
version of this article (doi:10.1007/s40121-013-0020-8)
contains supplementary material, which is available to
authorized users.
T. Mesple`de  M. A. Wainberg (&)
McGill University AIDS Centre, Lady Davis Institute




Division of Experimental Medicine, Faculty
of Medicine, McGill University, Montre´al,
QC, Canada
M. A. Wainberg
Department of Microbiology and Immunology,
Faculty of Medicine, McGill University, Montre´al,
QC, Canada
Enhanced content for this article is
available on the journal web site:
www.infectiousdiseases-open.com
123
Infect Dis Ther (2013) 2:83–93
DOI 10.1007/s40121-013-0020-8
antiretroviral drugs, HIV has the ability to
acquire resistance against integrase inhibitors
and this occurs through discrete mutations in
the integrase coding sequence (reviewed in
[5–8]). These mutations can be analyzed
according to several genotyping resistance
interpretation algorithms.
The issue of whether various integrase
inhibitors may be used sequentially, i.e., in a
sequential strategy, is a subject of great potential
importance. Indeed, this concept has been
studied from the beginnings of the field of
antiretroviral therapy to develop strategies that
might enable patients to benefit from newer
classes of drugs, even if they had previously
failed therapy while on older compounds
against which resistance had developed [3]. In
some cases, newer compounds could be used
even within single drug classes to provide
patient benefit in the event of resistance. A
good example of this has been the use of
ritonavir-boosted darunavir (DRV) that has a
high genetic barrier for resistance for use in the
place of earlier protease inhibitors such as
nelfinavir (NFV) and ritonavir-boosted
lopinavir (LPV) that have lower genetic barriers
to resistance [9–12]. Due to the fact that
ritonavir helps to maintain higher levels of PIs
in the blood and tissues of treated individuals,
the action of these compounds is prolonged and
their genetic barrier for resistance is increased.
It has also long been established that
members of different drug families may be
used even if resistance has developed against
members of other drug classes. As an example,
the development of drug resistance to the
NNRTI family of compounds can often be
confronted through the use of protease
inhibitors, since no cross-resistance exists
between these two drug classes. More recently,
newer NNRTI compounds that have somewhat
distinct resistance profiles have also been
developed to provide benefits to patients when
these compounds are used as a part of a second-
line regimen [13].
In this context, the discovery of integrase
strand transfer inhibitors (INSTIs) is important
as a means of extending therapeutic options for
individuals living with HIV. The integrase gene
and enzyme of HIV were recognized early to be
a potential therapeutic target and were shown
to be susceptible to inhibition by
oligonucleotides and synthetic peptides as
early as 1995 [14, 15]. However, a seminal
study only described the first promising small
compound targeting integrase in 2000 [16].
This, in turn, has led to the development of all
currently approved integrase inhibitors.
In the USA, INSTIs currently available for
HIV treatment include raltegravir (RAL),
elvitegravir (EVG), and dolutegravir (DTG).
Integration is a two-step reaction catalyzed
by the HIV integrase protein (reviewed in [17,
18]). The first step consists of the processing
of the 30 end of the newly retrotranscribed
double-stranded viral DNA and is followed by
the strand transfer reaction that results in the
irreversible insertion of the viral genome into
the host DNA. RAL, EVG, and DTG specifically
inhibit the strand transfer step of integration
[16, 19]. INSTIs have demonstrated long-term
safety and efficacy [20–24] for the treatment of
individuals living with multiple HIV subtypes
[25–27]. Here, we review the use of INSTIs in
first- and second-line HIV treatment regimens,
as well as the potential to use these drugs
sequentially after treatment failure as well as
the issue of resistance.
METHODS
The analysis in this article is based on
previously conducted studies, and does not
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involve any new studies of human or animal
subjects performed by any of the authors.
Clinical studies reviewed in this manuscript
were deemed important to the field of HIV
integrase inhibitors by the authors. Most of
these studies included large cohorts of patients.
We also searched PubMed using the terms
‘‘raltegravir’’, ‘‘elvitegravir’’, and ‘‘dolutegravir’’
as well as both the previous and brand names
for these drugs.
INTEGRASE INHIBITORS FOR FIRST-
AND SECOND-LINE TREATMENT
INSTIs have been used in clinical trials in
antiretroviral treatment-naı¨ve individuals
living with HIV (Table 1) [24, 28–47]. Both
RAL [24, 28–32] and cobicistat (c)-boosted EVG
[33, 34] have demonstrated non-inferiority to
efavirenz (EFV) when co-administered in
combination with tenofovir (TDF)/
emtricitabine (FTC). EVG/c is also non-inferior
to ATV/r when combined with TDF/FTC [35,
36]. Non-inferiority was also demonstrated for
DTG compared to EFV in the SPRING-1 (A Dose
Ranging Trial of GSK1349572 and 2 NRTI in
HIV-1 Infected, Therapy Naive Subjects) study
in which patients were randomized to receive
either TDF/FTC or abacavir (ABC)/lamivudine
(3TC) [37, 38]. More recently, the SINGLE (A
Trial Comparing GSK1349572 50 mg Plus
Abacavir/Lamivudine Once Daily to Atripla)
study compared DTG/abacavir ABC/3TC to
EFV/TDF/FTC and showed that the former
regimen offered a superior virological response
than the latter [39]. Although EVG is co-
formulated in a single pill with cobicistat
(c) plus FTC/TDF, RAL and DTG might also be
able to be co-formulated with nucleoside drugs,
and all of the INSTIs can probably be co-
formulated with protease inhibitors for use in
first-line treatment [48–54].
Importantly, INSTIs can be used for second-
line treatment against HIV strains that are
resistant against other drug classes, including
NRTI, NNRTI, and PI [55–62] (Table 1). In
particular, RAL was shown to be efficacious for
patients who displayed resistance to three
classes of drugs other than INSTIs [58]. In
addition, RAL combined with a ritonavir-
boosted PI was non-superior to ritonavir-
boosted PIs plus two or three NRTIs in patients
who had previously failed NNRTI-based
treatments [40]. RAL was also non-inferior to
LPV/r as a second-line drug for patients who
had failed regimens consisting of a NNRTI and
two NRTIs [41].
Treatment-experienced patients can also
benefit from the use of INSTIs for reasons of
toxicity, convenience, or absence of drug
interactions [41, 63, 64]. Although switching
from LPV/r/TDF/FTC to RAL/DRV/r in
individuals with suppressed viral load resulted
in sustained viral suppression, it did not
improve renal function at week 48 [42]. In
contrast, RAL has a positive impact on bone
mineral density compared to standard second-
line treatments [5]. Whether treatment
intensification with INSTIs might benefit
individuals with suppressed viral loads is
beyond the scope of this review [65–69].
Studies have compared the efficacy of the
different INSTIs in suppressing HIV viral load. In
the 145 Study, EVG demonstrated non-
inferiority to RAL at weeks 48 and 96 in highly
treatment-experienced patients [43, 44]. DTG
was non-inferior to RAL in attainment of viral
suppression in treatment-naı¨ve individuals at
week 48 [45]. In contrast, DTG performed better
than RAL in highly treatment-experienced
INSTI-naı¨ve individuals who were enrolled in a
Infect Dis Ther (2013) 2:83–93 85
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study termed SAILING (A Study of GSK1349572
Versus Raltegravir (RAL) With Investigator
Selected Background Regimen in Antiretroviral-
Experienced, Integrase Inhibitor-Naive Adults)
[46]. Overall INSTI-based regimens have shown
low toxicity and an absence of unfavorable
drug–drug interactions. The yearly costs of the
various INSTI-containing regimens are
comparable among the three drugs, i.e.,
approximately 30,000 USD/year [70].
SEQUENTIAL STRATEGY
FOR THE USE OF INTEGRASE
INHIBITORS AND THE ISSUE
OF RESISTANCE
The concept of sequential strategy in regard to
integrase inhibitors has not been fully explored.
Although little information is available on this
subject, the following facts are well-known.
First, it is unlikely that RAL and EVG will ever
Table 1 Summary of the major clinical trials reviewed in this publication
Study name Tested regimen Reference regimen Antiviral activity of the
tested regimen compared





RAL ? TDF/FTC vs. EFV ? TDF/FTC Non-inferiority [24, 28–32]
GS-US-236-0102 EVG/c ? TDF/FTC vs. EFV ? TDF/FTC Non-inferiority [33, 34]
GS-236-0103 EVG/c ? TDF/FTC vs. ATV/r ? TDF/FTC Non-inferiority [35, 36]
SPRING-1 DTG ? TDF/FTC or
ABC/3TC
vs. EFV ? TDF/FTC or
ABC/3TC
Non-inferiority [37, 38]
SINGLE DTG ? ABC/3TC vs. EFV ? TDF/FTC Superiority [39]
Study 145 EVG ? PI/r ? 3rd drug vs. RAL ? PI/r ? 3rd
drug
Non-inferiority [43, 44]
SPRING-2 DTG ? TDF/FTC or
ABC/3TC
vs. RAL ? TDF/FTC
or ABC/3TC
Non-inferiority [45]
SAILING DTG ? 1 or 2 active
drugs
vs. RAL ? 1 or 2 active
drugs
Superiority [46]
EARNEST RAL ? boosted PI vs. Boosted PI ? 2 or 3
NRTIs
Non-inferiority [40]
Second-Line RAL ? LPV/r vs. LPV/r ? 2 or 3
NRTIs
Non-inferiority [41]
FLAMINGO DTG ? TDF/FTC or
ABC/3TC
vs. DRV/r ? TDF/FTC
or ABC/3TC
Superiority [47]
RAL raltegravir, TDF tenofovir disoproxil fumarate, FTC emtricitabine, EFV efavirenz, EVG/c cobicistat-boosted
elvitegravir, ATV/r ritonavir-boosted atazanavir, ABC abacavir, 3TC lamivudine, DTG dolutegravir, PI protease inhibitor,
LPV/r ritonavir-boosted lopinavir
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be able to be used sequentially in therapy, since
the resistance profiles of these two compounds
overlap to considerable extent [5, 6]. The only
possibility for use of these compounds in
sequential fashion might be if a change in
therapy is contemplated at a time that
resistance has not yet developed against either
of these agents. The rationale for such a
substitution could include the fact that RAL is
a twice-daily drug and that some patients might
prefer to be on the once-daily regimen of co-
formulated EVG/c/TDF/FTC. In contrast, there
are some patients who cannot take a
pharmacological booster such as cobicistat for
reasons of drug interactions and who might
need instead to take the twice-daily regimen of
RAL, complemented by two members of the
nucleoside family of drugs [70].
The use of DTG to rescue patients who
have first developed resistance to RAL has also
been studied and documented [71]. In almost
all cases, it appears as though some measure of
patient benefit can be obtained if DTG is used
to treat individuals who have developed
resistance to either RAL or EVG, after the
development of mutations in the integrase
gene that follow one of the well-described
resistance pathways for these compounds.
However, it should also be noted that DTG
may not be as effective in this setting as it is
in first-line therapy. Indeed, the VIKING (A
Pilot Study Assessing the Integrase Inhibitor
GSK1349572 in HIV-infected Persons With
Virus Resistant to Raltegravir) clinical trials in
which DTG was used to rescue patients who
first developed resistance against RAL showed
that patients will have to receive DTG bid
dosing at a total intake that is double the dose
of DTG that is commonly used in first-line
therapy [71]. The results also suggest that
patients who first develop mutations that
follow the RAL/EVG 148/140 mutational
pathway are less likely to respond to DTG
than are INSTI-naı¨ve individuals. This raises
the important question of whether DTG can
be saved for use as part of a second-line
regimen, instead of being used in first-line
therapy. Clearly, patients who have failed RAL
or EVG and who have few other treatment
options might benefit from the use of DTG
and should be treated with this drug.
However, this does not mean that DTG
should be saved for use in later treatment
regimens. In support of this, the FLAMINGO
(Dolutegravir Compared to Darunavir/
Ritonavir, Each in Combination With Dual
Nucleoside Reverse Transcriptase Inhibitors
(NRTIs) in ART-naive Subjects) study recently
demonstrated the superiority of DTG over
DRV/r in first-line therapy, when patients
also received two nucleos(t)ides [47].
SHOULD DTG BE USED
AS A FIRST-LINE DRUG?
The danger of delaying the use of DTG is that
significant numbers of individuals who develop
resistance to RAL and/or EVG may, by that time,
have lost their ability to respond in fully
efficacious fashion to DTG. For example, the
results of the VIKING studies raise the issue of
durability of responsiveness to a DTG-based
regimen in second-line therapy after relevant
INSTI mutations for RAL and EVG are already in
place.
Further information on this topic is provided
by the results of the SAILING study that
evaluated the use of RAL vs. DTG in a context
in which previously treatment-experienced
patients had received therapy with many other
types of drugs but not with INSTIs. Moreover, the
patients in this trial had developed resistance
against many of the compounds that were used
Infect Dis Ther (2013) 2:83–93 87
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in prior therapy. Accordingly, almost all of them
had compromised background regimens that
involved the use of the various antiretroviral
compounds that were employed. The results of
the SAILING study show clearly that DTG
outperformed RAL in terms of percentage of
patients who achieved significant drops in viral
load [46]. This is important, as it suggests that
DTG is a more potent compound than RAL when
either of these drugs is used in a salvage setting
for patients who have previously failed
traditional drug regimens that did not include
an INSTI. At the same time, patients in the RAL
arm of the trial who developed resistance against
the latter compound did so due to development
of mutations that are associated with the latter
drug. In contrast, patients in the DTG arm of the
trial developed resistance in very few cases. Two
individuals developed the R263K mutation [72]
that had earlier been shown to be of potential
significance for DTG on the basis of tissue culture
selection studies [73]. Accordingly, it appears
that resistance to DTG in the clinic may be very
difficult to develop, even in the case of patients
who have previously failed other drug regimens
and who are currently being treated with DTG,
almost in the context of functional
monotherapy. This suggests that it may be very
difficult to develop resistance against DTG under
circumstances in which this compound is used as
part of a first-line INSTI regimen. This may be
because the mutations that develop against DTG,
when the latter is used in first-line therapy, are
ones that significantly diminish viral replication
capacity [73, 74].
In contrast, the use of DTG as part of a
second-line INSTI regimen may be more laden
with problems, given the fact that mutations at
positions 148, 140, and elsewhere within the
viral genome, that are associated with resistance
to RAL and EVG, may interfere with the ability
of DTG to perform well. Moreover, the use of
DTG to treat previously INSTI-experienced
patients, with resistance to RAL and/or EVG,
may lead to the selection of additional
mutations that may further compromise
therapy and cause cross-resistance [71].
Notably, in vitro studies suggest that the very
rare individuals who may fail DTG treatment
following emergence of the R263K mutation
Table 2 Representation of the potential evolution of HIV-1 following therapy of previously treatment-naı¨ve individuals


















Q148H/K/R ? E138A/K; Q148H/K/R ? G140S/A;
Q148H/E138A/G140S/Y143H
Dolutegravir R263 K None Viral
suppression
In rare cases, the emergence of resistance mutations in patients treated with raltegravir or elvitegravir can lead to virological
failure (top). Virological failure with resistance mutations in treatment-naı¨ve patients treated with dolutegravir has not been
reported (bottom)
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may still be treatable with RAL but not with
EVG [74]. As stated, the results of the VIKING
studies showed that many patients who
possessed mutations at positions 148 and 140
within integrase did not respond well to DTG
[71]. In addition, such patients commonly
developed additional mutations associated
with the RAL/EVG resistance pathway. Thus,
the potential sequential use of integrase
inhibitors may be problematic, and the use of
DTG in second-line regimens after resistance
has developed against either RAL or EVG may
ultimately represent a hazard to the long-term
performance of DTG in the clinic. Of course, the
choice of which INSTI to use in first-line
regimens will be made by physicians in
consultation with their patients based on
considerations of drug efficacy, tolerability,
safety, and ease of dosing. A summary of
resistance pathways involving the use of
various INSTIs to treat patients in first-line
therapy can be found in Table 2.
CONCLUSION
INSTIs are the most recent class of antiretroviral
drugs. INSTIs can and should be used as part of
first- and second-line regimens to treat
individuals living with HIV. Due to its high
genetic barrier for resistance, DTG may be used
to treat patients who have previously failed
treatment with RAL or EVG, but only under the
circumstances described above. Overall, INSTIs
are a major advance in the management of
individuals living with HIV.
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